WDNA vs. SBIO
WDNA (WisdomTree BioRevolution Fund) and SBIO (ALPS Medical Breakthroughs ETF) are both Health & Biotech Equities funds - WDNA tracks the WisdomTree BioRevolution Index while SBIO tracks the S-Network Medical Breakthroughs Index. Both are passively managed. Over the past 5 years, WDNA returned -4.78%/yr vs 3.16%/yr for SBIO. Their correlation of 0.85 suggests significant overlap in exposure. WDNA charges 0.45%/yr vs 0.50%/yr for SBIO.
Performance
WDNA vs. SBIO - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, WDNA achieves a 8.96% return, which is significantly higher than SBIO's 1.95% return.
WDNA
- 1D
- 2.94%
- 1M
- 2.56%
- YTD
- 8.96%
- 6M
- 10.44%
- 1Y
- 50.50%
- 3Y*
- 3.54%
- 5Y*
- -4.78%
- 10Y*
- —
SBIO
- 1D
- 2.35%
- 1M
- -5.55%
- YTD
- 1.95%
- 6M
- 4.13%
- 1Y
- 68.86%
- 3Y*
- 18.38%
- 5Y*
- 3.16%
- 10Y*
- 8.03%
WDNA vs. SBIO - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
WDNA WisdomTree BioRevolution Fund | 8.96% | 22.68% | -14.18% | -2.07% | -26.29% | -5.27% |
SBIO ALPS Medical Breakthroughs ETF | 1.95% | 55.07% | 3.81% | 8.68% | -28.08% | -8.21% |
Correlation
The correlation between WDNA and SBIO is 0.78, which is moderate. They share some common price drivers but move independently often enough to provide real diversification benefit when combined.
| Correlation | |
|---|---|
Correlation (1Y) Calculated over the trailing 1-year period | 0.78 |
Correlation (3Y) Calculated over the trailing 3-year period | 0.82 |
Correlation (5Y) Calculated over the trailing 5-year period | 0.85 |
Correlation (All Time) Calculated using the full available price history since Jun 4, 2021 | 0.85 |
The correlation between WDNA and SBIO has been stable across timeframes, ranging from 0.78 to 0.85 - a consistent structural relationship.
WDNA vs. SBIO - Sectors Allocation Comparison
Sectors
WDNA
SBIO
Healthcare
Basic Materials
-
Consumer Defensive
-
Energy
-
Communication Services
-
-
Consumer Cyclical
-
-
Financial Services
-
Industrials
-
-
Real Estate
-
-
Technology
-
-
Utilities
-
-
Healthcare
WDNA
SBIO
Basic Materials
WDNA
SBIO
-
Consumer Defensive
WDNA
SBIO
-
Energy
WDNA
SBIO
-
Communication Services
WDNA
-
SBIO
-
Consumer Cyclical
WDNA
-
SBIO
-
Financial Services
WDNA
-
SBIO
Industrials
WDNA
-
SBIO
-
Real Estate
WDNA
-
SBIO
-
Technology
WDNA
-
SBIO
-
Utilities
WDNA
-
SBIO
-
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
WDNA vs. SBIO — Risk / Return Rank
WDNA
SBIO
WDNA vs. SBIO - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for WisdomTree BioRevolution Fund (WDNA) and ALPS Medical Breakthroughs ETF (SBIO). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
| WDNA | SBIO | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -0.38 | ||
| Sortino ratioReturn per unit of downside risk | -0.37 | ||
| Omega ratioGain probability vs. loss probability | 1.32 | 1.38 | -0.05 |
| Calmar ratioReturn relative to maximum drawdown | 4.34 | 5.47 | -1.13 |
| Martin ratioReturn relative to average drawdown | 9.85 | 16.23 | -6.38 |
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month. | |||
Loading charts...
Sharpe Ratios by Period
| WDNA | SBIO | Difference | |
|---|---|---|---|
Sharpe Ratio (1Y)Calculated over the trailing 1-year period | 1.98 | 2.35 | -0.38 |
Sharpe Ratio (5Y)Calculated over the trailing 5-year period | -0.19 | 0.09 | -0.29 |
Sharpe Ratio (10Y)Calculated over the trailing 10-year period | — | 0.24 | — |
Sharpe Ratio (All Time)Calculated using the full available price history | -0.19 | 0.22 | -0.41 |
Drawdowns
WDNA vs. SBIO - Drawdown Comparison
The maximum WDNA drawdown since its inception was -58.87%, smaller than the maximum SBIO drawdown of -63.06%. Use the drawdown chart below to compare losses from any high point for WDNA and SBIO.
Loading charts...
Drawdown Indicators
| WDNA | SBIO | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -58.87% | -63.06% | +4.19% |
Max Drawdown (1Y)Largest decline over 1 year | -11.70% | -12.66% | +0.96% |
Max Drawdown (3Y)Largest decline over 3 years | -38.25% | -42.44% | +4.19% |
Max Drawdown (5Y)Largest decline over 5 years | -58.87% | -53.10% | -5.77% |
Max Drawdown (10Y)Largest decline over 10 years | — | -63.06% | — |
Current DrawdownCurrent decline from peak | -29.86% | -14.84% | -15.02% |
Average DrawdownAverage peak-to-trough decline | -35.64% | -28.44% | -7.20% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 5.14% | 4.26% | +0.88% |
Volatility
WDNA vs. SBIO - Volatility Comparison
The current volatility for WisdomTree BioRevolution Fund (WDNA) is 7.35%, while ALPS Medical Breakthroughs ETF (SBIO) has a volatility of 9.85%. This indicates that WDNA experiences smaller price fluctuations and is considered to be less risky than SBIO based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| WDNA | SBIO | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 7.35% | 9.85% | -2.50% |
Volatility (6M)Calculated over the trailing 6-month period | 16.59% | 22.76% | -6.17% |
Volatility (1Y)Calculated over the trailing 1-year period | 25.66% | 29.40% | -3.74% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 25.08% | 33.57% | -8.49% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 25.07% | 33.18% | -8.11% |
WDNA vs. SBIO - Expense Ratio Comparison
WDNA has a 0.45% expense ratio, which is lower than SBIO's 0.50% expense ratio.
Dividends
WDNA vs. SBIO - Dividend Comparison
WDNA's dividend yield for the trailing twelve months is around 4.19%, while SBIO has not paid dividends to shareholders.
| Position | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
SBIO ALPS Medical Breakthroughs ETF | 0.00% | 0.00% | 3.55% | 0.22% | 0.00% | 0.00% | 0.00% | 0.04% | 2.79% | 1.77% |
WDNA WisdomTree BioRevolution Fund | 4.19% | 4.57% | 0.75% | 0.80% | 0.38% | 0.10% | 0.00% | 0.00% | 0.00% | 0.00% |
Frequently Asked Questions
WDNA and SBIO have a correlation of 0.78, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
SBIO has higher volatility (9.85%) compared to WDNA (7.35%). In terms of maximum drawdown, WDNA dropped -58.87% vs SBIO's -63.06%.
On 5-year performance, SBIO leads with 3.16% vs -4.78% for WDNA. On fees, WDNA is cheaper at 0.45% per year. On volatility, WDNA has been the lower-risk option at 7.35%. The better choice depends on whether you care most about return, fees, risk, or income.
Over the 5-year period, SBIO has performed better with a 3.16% return vs -4.78%. Past performance does not guarantee future results, so compare this with risk, fees, and fund exposure.
WDNA is cheaper with a 0.45% expense ratio, compared with 0.50% for SBIO.
WDNA has the higher dividend yield at 4.19%, compared with 0.00% for SBIO.
WDNA tracks WisdomTree BioRevolution Index, while SBIO tracks S-Network Medical Breakthroughs Index. They also come from different issuers: WisdomTree and SS&C. Their fees differ too: 0.45% for WDNA and 0.50% for SBIO.
SBIO currently has the higher Sharpe Ratio (2.35 vs 1.98), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.
Find the right allocation for WDNA and SBIO
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer